Episode Details
Back to Episodes
Moderna & Korea University Team Up for Hantavirus mRNA Vaccine
Description
Moderna partners with Korea University to develop an mRNA hantavirus vaccine, following a deadly outbreak on a Dutch cruise ship. The collaboration, initiated in September 2023, boosts Modernas stock as investors eye the potential of their mRNA platform. Hantavirus, primarily spread through rodent droppings, causes around 50,000 severe cases annually, with a fatality rate of up to 40% in South America. The Andean strain, responsible for the cruise ship outbreak, can transmit human-to-human. Early mouse trials show promising results, but the vaccine faces significant hurdles before human trials. The World Health Organization emphasizes the importance of preemptive vaccine development, like Modernas work on bird flu.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/b98987dbd8096dcb